

Extended pharmacological profiles of rat P2Y₂ and rat P2Y₄ receptors and their sensitivity to extracellular H⁺ and Zn²⁺ ions

¹Scott S. Wildman, ¹Robert J. Unwin & *¹Brian F. King

¹Department of Physiology (Centre for Nephrology), Royal Free Campus, Royal Free and University College Medical School, University College London (UCL), Rowland Hill Street, Hampstead, London NW3 2PF, U.K.

1 Two molecularly distinct rat P2Y receptors activated equally by adenosine-5'-triphosphate (ATP) and uridine-5'-triphosphate (UTP) (rP2Y₂ and rP2Y₄ receptors) were expressed in *Xenopus* oocytes and studied extensively to find ways to pharmacologically distinguish one from the other.

2 Both P2Y subtypes were activated fully by a number of nucleotides. Tested nucleotides were equipotent at rP2Y₄ (ATP=UTP=CTP=GTP=ITP), but not at rP2Y₂ (ATP=UTP>CTP>GTP>ITP). For dinucleotides (Ap_nA, n=2–6), rP2Y₄ was only fully activated by Ap₄A, which was as potent as ATP. All tested dinucleotides, except for Ap₂A, fully activated rP2Y₂, but none were as potent as ATP. ATP_γS and BzATP fully activated rP2Y₂, whereas ATP_γS was a weak agonist and BzATP was inactive (as an agonist) at rP2Y₄ receptors.

3 Each P2Y subtype showed different sensitivities to known P2 receptor antagonists. For rP2Y₂, the potency order was suramin >> PPADS = RB-2 > TNP-ATP and suramin was a competitive antagonist (pA₂, 5.40). For rP2Y₄, the order was RB-2 >> suramin > PPADS > TNP-ATP and RB-2 was a competitive antagonist (pA₂, 6.43). Also, BzATP was an antagonist at rP2Y₄ receptors.

4 Extracellular acidification (from pH 8.0 to pH 5.5) enhanced the potency of ATP and UTP by 8–10-fold at rP2Y₄ but did not affect agonist responses at rP2Y₂ receptors.

5 Extracellular Zn²⁺ ions (0.1–300 μM) coapplied with ATP inhibited agonist responses at rP2Y₄ but not at rP2Y₂ receptors.

6 These two P2Y receptors differ significantly in terms of agonist and antagonist profiles, and the modulatory activities of extracellular H⁺ and Zn²⁺ ions. These pharmacological differences will help to distinguish between rP2Y₂ and rP2Y₄ receptors, *in vivo*.

British Journal of Pharmacology (2003) **140**, 1177–1186. doi:10.1038/sj.bjp.0705544

Keywords: GPCR; purinoceptor; P2Y receptor; P2Y₂ receptor; P2Y₄ receptor; P2U receptor; extracellular pH; Zinc; oocyte

Abbreviations: ATP, adenosine-5'-triphosphate; ATP_γS, adenosine-5'-O-(thiotriphosphate); 2-MeSATP, 2-methylthioATP; αβ-meATP, α,β-methyleneATP; βγ-meATP, β,γ-methyleneATP; BPAE, bovine pulmonary-artery endothelium; BzATP, 2',3'-O-(4-benzoylbenzoyl)ATP; CTP, cytosine-5'-triphosphate; GTP, guanosine-5'-triphosphate; ITP, inosine-5'-triphosphate; UTP, uridine-5'-triphosphate; Ap_nA, P¹-P⁽ⁿ⁾-di(adenosine-5')phosphate; GPCR, G protein-coupled receptor; LGIC, ligand-gated ion-channel; PPADS, pyridoxal-5-phosphate-6-azophenyl-2',4'-disulphonic acid; RB-2, Reactive blue 2; SAR, structure-activity relationship; TNP-ATP, 2',3'-O-(2,4,6-trinitrophenyl)ATP; TPEN, N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenedi-amine; suramin, suramin hexasodium salt; Up_nU, P¹-P⁽ⁿ⁾-di(uridine-5')phosphate

Introduction

Prior to expression cloning, the P2U receptor was defined as a G-protein-coupled receptor activated equally by the purine and pyrimidine nucleotides adenosine-5'-triphosphate (ATP) and uridine-5'-triphosphate (UTP) (Dubyak, 1991; O'Connor *et al.*, 1991; Dubyak & El-Moatassim, 1993). Cell-surface receptors sensitive to these nucleotides (and, in some cases, other naturally occurring nucleoside triphosphates) have a widespread distribution in tissues and cell types of various species – including astrocytes, leukocytes, epithelium, endothelium, endocrine and exocrine glands, hepatocytes, vascular and visceral smooth muscle and others (Ralevic & Burnstock, 1998). A subdivision of ATP/UTP sensitive receptors was proposed on the basis that suramin hexasodium

salt (suramin) blocked some, but not all, P2U receptors in mammalian tissues (Dainty *et al.*, 1994; Ralevic & Burnstock, 1998).

With the introduction of expression cloning, an ATP/UTP receptor was isolated from mouse neuroblastoma (NG108-15) cells and human airway epithelial (CF/T43) cells (Lustig *et al.*, 1993; Parr *et al.*, 1994). Heterologous expression of these P2 receptors, in either *Xenopus laevis* oocytes or human 1321N1 astrocytoma cells, resulted in ATP- and UTP-mediated responses that signalled through the G_q/PLC_β/IP₃/Ca²⁺ pathway (Lustig *et al.*, 1993; Parr *et al.*, 1994). The encoding cDNAs for these P2 receptors were defined as genes for the mouse and human P2Y₂ receptor, whereas cDNAs for another two P2 purinoceptors isolated from chick brain were classed as P2Y₁ and P2Y₃ (Barnard *et al.*, 1994; Von Kügelgen *et al.*, 1987). This nomenclature system still remains in place and has been expanded to include cDNAs for P2Y₄ to P2Y₁₄, most of

*Author for correspondence;

E-mail: b.king@ucl.ac.uk or b.king@rfc.ucl.ac.uk

Advance online publication: 27 October 2003

which encode functional nucleotide receptors (Abbracchio *et al.*, 2003).

Shortly after the molecular identification of the P2Y₂ receptor, the human P2Y₄ receptor was cloned and, when expressed in 1321N1 cells, this metabotropic receptor was shown to be sensitive to UTP and insensitive to ATP (Communi *et al.*, 1995; Nguyen *et al.*, 1995). This human P2Y₄ receptor was viewed as a pyrimidinoceptor that was both structurally and phenotypically distinct from the ATP/UTP-sensitive P2Y₂ receptors. However, the subsequent cloning of rat and mouse P2Y₄ receptors – each greater than 80% identical to the human isoform of P2Y₄ – resulted in a metabotropic receptor that was activated equally by ATP and UTP in all expression systems employed (*Xenopus* oocytes, Jurkat cells and 1321N1 cells) (Bogdanov *et al.*, 1998; Webb *et al.*, 1998; Kennedy *et al.*, 2000; Lazarowski *et al.*, 2001; Suarez-Heurta *et al.*, 2001). Therefore, the rodent P2Y₄ was found to be phenotypically similar to the rat and human P2Y₂ receptor.

From the functional evidence available at the time, it was proposed that several pharmacological features might help to distinguish P2Y₂ isoforms from the rat P2Y₄ receptor (King *et al.*, 1998). These features included: (i) the potency of UTP and ATP seemed higher at P2Y₂ receptors; (ii) adenosine-5'-*O*-(thiotriphosphate) (ATP_γS) was a full agonist at P2Y₂, but weakly stimulated P2Y₄; (iii) in contrast, inosine-5'-triphosphate (ITP) was a full agonist at P2Y₄, but weakly stimulated P2Y₂; (iv) suramin blocked P2Y₂, but not P2Y₄ receptors. However, many of these distinguishing pharmacological features were gleaned from published data taken from unrelated studies and have not been tested directly.

In the present study, the issue of differentiating rat P2Y₂ from rat P2Y₄ receptors has been revisited. For the first time, we demonstrate the pharmacological means to distinguish between these two ATP/UTP-sensitive P2Y receptor subtypes. A part of this study has been presented elsewhere (Wildman *et al.*, 2002).

Methods

Oocyte preparation

Defolliculated *Xenopus* oocytes were selected to express recombinant P2Y receptors because they do not possess endogenous P2 receptors, lack functional P1 receptors and, furthermore, surface ATPase activity is exceedingly low with no effective breakdown of superfused UTP, ATP and adenine-based dinucleotides (P¹-P⁽ⁿ⁾-di(adenosine-5')phosphate (Ap_nA) family) for the superfusion periods used in this study (King *et al.*, 1996a; Pintor *et al.*, 1996). To prepare these cells, *Xenopus laevis* frogs were anaesthetized with Tricaine (0.4% wv⁻¹ in tap water), killed by decapitation, and the ovarian lobes surgically removed. Oocytes (stages V and VI) were defolliculated by a two-step process involving collagenase treatment (Type IA, 1 mg ml⁻¹ in a Ca²⁺-free Ringer solution, for 2 h) followed by stripping away the follicular layer with fine forceps (in double-strength Ca²⁺-free Ringer solution to help shrink oocytes).

Prepared oocytes were stored in a Barth's solution (pH 7.50) containing 110 mM NaCl, 1 mM KCl, 7.5 mM Tris-HCl, 0.33 mM Ca(NO₃)₂, 0.41 mM CaCl₂, 0.82 mM MgSO₄, 2.4 mM

NaHCO₃, supplemented with 50 μg l⁻¹ gentamycin sulphate. Defolliculated oocytes were injected cytosolically (40 nl) with either rP2Y₄ or P2Y₂ cRNA (1 μg μl⁻¹), then incubated for 48 h at 18°C in Barth's solution and, thereafter, kept at 4°C in Barth's solution for up to 7 days and until used in electrophysiological experiments.

Electrophysiological recordings

Agonist-activated membrane currents were recorded under voltage-clamp conditions ($V_h = -60$ mV) from cRNA-injected oocytes using twin-electrode amplifiers (Axoclamp 2A and 2B; Axon Instruments, Union City, CA, U.S.A.). The voltage-recording and current-recording microelectrodes (1–5 MΩ tip resistance) were filled with 3.0 M KCl. The evoked membrane currents were calcium-activated chloride currents ($I_{Cl,Ca}$), which resulted from P2Y receptor stimulation of the G_q/PLC_β/IP₃/Ca²⁺ pathway in oocytes (Lustig *et al.*, 1993). Oocytes were superfused with a Ca²⁺-Ringer solution (12 ml min⁻¹, pH 7.50, at 18°C) containing 110 mM NaCl, 2.5 mM KCl, 5 mM HEPES and 1.8 mM CaCl₂. Where stated, the pH of the bathing solution was adjusted using either 1.0 N HCl or 1.0 N NaOH to achieve the desired level. Electrophysiological data were stored on a computer using an MP100 WSW interface (Biopac Systems, Goleta, CA, U.S.A.) and analysed using the software package *Acqknowledge III* (Biopac Systems).

Analysis of drug actions

All drugs were superfused by a gravity-fed continuous flow system, which allowed for rapid addition and washout. Agonists were added for 90 s or until the evoked current reached a peak, then washed out with Ringer solution for a period of 1 h. For all agonist concentration–response (*C/R*) curves, data were normalised to the maximum current (I_{max}) evoked by ATP (30 μM or 100 μM for rP2Y₄ and rP2Y₂, respectively; at pH 7.5) in the oocyte under study. The agonist concentration that evoked 50% of the maximum response (EC₅₀) was taken from Hill plots of the transform, log ($I/I_{max} - I$), where I is the current evoked by each concentration of agonist. The Hill coefficient (n_H) was taken from the slope of the Hill plots.

The inhibitory activity of P2 antagonists was tested by adding each antagonist in increasing concentrations, each applied 20 min prior to and during the addition of ATP (~EC₇₀ concentration, 3 or 10 μM ATP for rP2Y₄ and rP2Y₂, respectively). Where the activity of antagonists was tested at a lower pH level (pH 5.5), the EC₇₀ concentrations of ATP were 300 nM and 10 μM for rP2Y₄ and rP2Y₂, respectively. The antagonist concentration that reduced ATP responses by 50% (IC₅₀) was taken from the inhibition curves. The reversibility of receptor blockade was tested after prolonged (> 2 h) washout of antagonists. pA₂ values were determined by Schild analysis.

C/R curves for the modulatory activity of Zn²⁺ ions were constructed against submaximal concentrations of ATP (3 or 10 μM ATP for rP2Y₄ and rP2Y₂, respectively) and thereafter data were normalized to the amplitude of control ATP responses.

Data are presented as mean ± s.e.m. of three or more sets of data obtained from different oocyte batches. Significant differences were determined by Student's *t*-test (using Instat

v2.05A, GraphPad Software, San Diego, CA, U.S.A.). Concentration–response curves and inhibition curves were fitted by nonlinear regression analysis using commercial software (Prism v3.0, GraphPad).

Drugs

ATP, other nucleotides and drugs were purchased from Sigma-Aldrich (Poole, Dorset, U.K.). Suramin was a gift from Bayer plc (Newbury, Berkshire, U.K.), while 2',3'-*O*-(2,4,6-trinitrophenyl)ATP (TNP-ATP) was obtained from Molecular Probes (Eugene, OR, U.S.A.). All reagents, including ZnCl₂, were AnalaR grade from Sigma-Aldrich. Drugs were prepared in a Ca²⁺-Ringer solution and the extracellular pH was adjusted to the desired level.

DNA constructs

The rat P2Y₂ receptor cDNA (U56839) was kindly provided by Dr Claude Desgranges and Dr Cheikh Seye (INSERM U441, Pessac, FRANCE) (as described in Seye *et al.*, 1997). We have previously isolated the rat P2Y₄ receptor cDNA (Y14705) (as described in Bogdanov *et al.*, 1998).

Results

Activation by nucleoside triphosphates

Previously, rat P2Y₄ (rPY₄) receptors expressed in human 1321N1 astrocytoma cells were shown to be activated by a wide range of nucleoside triphosphates (Kennedy *et al.*, 2000). Here, we have confirmed that UTP, ATP, cytosine-5'-triphosphate (CTP), guanosine-5'-triphosphate (GTP) and ITP were active at rP2Y₄ expressed in *Xenopus* oocytes (Figure 1a,c), also established that the same range of nucleotides were active at rat P2Y₂ (rP2Y₂) receptors expressed in oocytes (Figure 1d) and, in both cases, all tested nucleotides were found to be full agonists. These five nucleotides were equipotent at rP2Y₄ (Table 1), whereas at rP2Y₂ only UTP and ATP were equipotent and CTP, GTP and ITP – in this order – were progressively less potent (Table 1). It has already been shown that BzATP (2',3'-*O*-(4-benzoylbenzoyl)ATP) is an agonist at human P2Y₂ expressed in 1321N1 cells (Erb *et al.*, 1993) and, therefore, we confirmed that BzATP also activated rat P2Y₂ in oocytes (Figure 1b,d). Here BzATP was as potent as UTP and ATP (Table 1), but it proved to be virtually inactive at rP2Y₄ receptors (at 1 mM, 6.4 ± 0.9% of the maximum ATP response; *n* = 3) (Figure 1b,c).

Activation by adenine dinucleotides

Diadenosine polyphosphates (Ap_{*n*}As, *n* = 2–6) are active at a number of native and recombinant P2 receptors (Hoyle *et al.*, 2001) and, so, the Ap_{*n*}A family was tested at rat P2Y receptor subtypes. At rP2Y₄, the tetraphosphate molecule Ap₄A (EC₅₀, 2.6 ± 1.6 μM, *n* = 4) was as potent as ATP, whereas the remainder of the tested dinucleotides were either partial agonists (<25% of the maximum ATP response) or inactive (Figure 2a; Table 1). The rP2Y₂ receptor was found to be less selective and was fully activated by all of the tested adenine dinucleotides, except for the diphosphate molecule Ap₂A, which




Figure 1 Activation by nucleoside triphosphates. (a) Naturally occurring nucleoside triphosphates (ATP, UTP, CTP, GTP and ITP; at 30 μM, the EC₁₀₀) activated rP2Y₄ receptors and evoked calcium-dependent chloride currents (*I*_{Cl,Ca}) in *Xenopus* oocytes. Water-injected control oocytes failed to respond to any of these nucleotides. However, the same range of agonists also activated rP2Y₂ receptors (records not shown). (b) The synthetic nucleotide BzATP (30 μM) was inactive at rP2Y₄ receptors, but the same compound (100 μM, the EC₁₀₀) was fully active at rP2Y₂ receptors. (c, d) The concentration/response (*C/R*) curves for agonists at each of the two P2Y receptor subtypes. Data are expressed as mean ± s.e.m. (*n* = 3–6). The EC₅₀ values of agonists and Hill coefficients (*n*_H) for *C/R* curves are given in Table 1. In (a), all records were evoked from the same oocyte whereas in (b), paired records were from separate oocytes (*V*_h = –60 mV).

was a partial agonist (at 10 mM, 21.2 ± 3.9% of the maximum ATP response) (Figure 2b; Table 1). At rP2Y₂, the most potent dinucleotide was also Ap₄A (EC₅₀, 6.5 ± 0.7 μM, *n* = 4).

Table 1 Agonist and antagonist potency at recombinant P2Y receptors

	rP2Y ₄		rP2Y ₂	
	EC ₅₀ (μ M)	n _H	EC ₅₀ (μ M)	n _H
UTP	1.8 ± 0.9	1.3 ± 0.3	3.6 ± 0.3	0.9 ± 0.3
ATP	1.5 ± 0.8	1.0 ± 0.2	2.7 ± 0.9	1.1 ± 0.3
CTP	1.2 ± 0.1	1.1 ± 0.2	6.8 ± 0.5	1.0 ± 0.2
GTP	1.4 ± 0.1	1.0 ± 0.3	9.7 ± 0.8	1.1 ± 0.2
ITP	1.6 ± 0.3	1.2 ± 0.2	20.9 ± 0.9	0.9 ± 0.3
Ap ₂ A	Inactive		1,029 ± 21 ^a	1.1 ± 0.2
Ap ₃ A	5.7 ± 1.9 ^a	1.4 ± 0.7	23.8 ± 1.2	1.0 ± 0.2
Ap ₄ A	2.6 ± 1.6	0.7 ± 0.2	6.5 ± 0.7	1.1 ± 0.3
Ap ₅ A	3.4 ± 1.3 ^a	1.4 ± 0.5	20.3 ± 0.6	1.3 ± 0.1
Ap ₆ A	Inactive		26.5 ± 0.8	1.0 ± 0.2
BzATP	nd ^a	nd	4.7 ± 0.2	1.1 ± 0.2
ATP _γ S	5.4 ± 0.3 ^a	1.9 ± 0.4	10.5 ± 0.7	1.1 ± 0.3
2-MeSATP	1.4 ± 0.2 ^a	1.5 ± 0.3	9.4 ± 0.5 ^a	1.4 ± 0.3

	rP2Y ₄		rP2Y ₂	
	IC ₅₀ (μ M)	n _H	IC ₅₀ (μ M)	n _H
BzATP	159 ± 19	1.2 ± 0.4	Nd	nd
PPADS	>1,000	nd	>10,000	nd
RB-2	18.5 ± 1.4	0.8 ± 0.2	>10,000	nd
Suramin	1027 ± 32	0.9 ± 0.2	8.9 ± 3.3	1.3 ± 0.5
TNP-ATP	>1000	nd	>10,000	nd

^aPartial agonist; nd, not determined.

Potency indices (EC₅₀, IC₅₀) and Hill coefficients (n_H) for a range of agonists and antagonists at rP2Y₄ receptors (left) and rP2Y₂ receptors (right) expressed in *Xenopus* oocytes. Data are expressed as mean ± s.e.m. (n = 3–6).




Figure 2 Activation by adenine dinucleotides. Concentration/response (*C/R*) relationships (a, b) for the adenine dinucleotide series (Ap_nA, n = 2–6) as agonists of rP2Y₄ receptors (top) and rP2Y₂ receptors (bottom) expressed in *Xenopus* oocytes. Ap_nA responses were normalised to the maximum ATP response evoked at each P2Y subtype. Data are expressed as mean ± s.e.m. (n = 3–7). Further details are given in the text and Table 1.

Activation by synthetic nucleotides

To conclude the study of agonists, some well-known synthetic nucleotides were tested at both P2Y receptor subtypes (Table 1). At rP2Y₂, ATP_γS was a full agonist but only a partial agonist at rP2Y₄ (24.2 ± 5.1% of maximum ATP response; n = 4). 2-methylthioATP (2-MeSATP) was a partial agonist at rP2Y₂ (33.8 ± 4.9% of maximum ATP response; n = 4) and rP2Y₄ (23.5 ± 3.9% of maximum ATP response; n = 4). Both α,β -methyleneATP ($\alpha\beta$ meATP) and β,γ -methyleneATP ($\beta\gamma$ meATP) (up to 100 μ M) were inactive at each P2Y receptor subtype.

Blockade of P2Y receptors

Comparatively little is known about the potency of classical P2 receptor antagonists at native P2U receptors in mammalian tissues – other than that some are suramin sensitive and some are not (Dainty *et al.*, 1994; Ralevic & Burnstock, 1998). Here, a short series of known P2 antagonists – Reactive blue 2 (RB-2), suramin, PPADS (pyridoxal-5-phosphate-6-azophenyl-2',4'-disulphonic acid) and TNP-ATP – was tested at rP2Y₄ and rP2Y₂ receptors (Figure 3a,b).

For rP2Y₄, RB-2 was the most potent blocking agent (IC₅₀, 18.5 ± 1.4 μ M, n = 4) and, in further experiments, it behaved as a competitive antagonist (pA₂, 6.43) – displacing the *C/R* curve for ATP to the right without reducing its maximum response (Figure 3c). Suramin and PPADS were relatively weak antagonists, requiring very high concentrations to block rP2Y₄ (Figure 3a), and each antagonist yielded predictive IC₅₀ values in the region of 1–10 mM (Table 1). TNP-ATP was inactive at 1 mM, although it did reduce ATP responses at higher concentrations (Figure 3a). Since BzATP was an agonist of very low efficacy, it was tested for antagonist activity and, at high concentrations, it blocked rP2Y₄ receptors (IC₅₀, 159 ± 19 μ M, n = 4) (Figure 3a).

For rP2Y₂, suramin was the most potent blocking agent (IC₅₀, 8.9 ± 3.3 μ M), and, in further experiments, it behaved as a competitive antagonist (pA₂, 5.40) – displacing the *C/R* curve for ATP to the right without reducing its maximum response (Figure 3d). PPADS, RB-2 and TNP-ATP were very weak antagonists (between 20 and 50% inhibition at 10 mM).

The blocking actions of suramin at both P2Y receptor subtypes, as well as that of BzATP and TNP-ATP, were reversible following a 1 h washout period. However, blockade by either RB-2 or PPADS required in excess of 2 h washout.

Modulatory actions of pH

It has been previously reported that changing extracellular pH altered the potency of agonists at native P1 (adenosine) receptors (Hiley *et al.*, 1995) and recombinant P2X receptors (King *et al.*, 1996b). Thus the effects of changing extracellular pH – over the range of pH 8.0–5.5 – were investigated for rP2Y₄ and rP2Y₂ receptors (Figure 4a,b).

With rP2Y₂, there were no significant differences in agonist potency at the four pH levels investigated (Figure 4b). However, a different picture emerged for rP2Y₄, where agonist potency was significantly altered under acidic conditions (Figure 4a, Table 2). ATP potency was increased three-fold at pH 6.5 and 10-fold at pH 5.5 (compared to agonist activity




Figure 3 Blockade of P2Y receptors. (a, b) Inhibition curves for a range of P2 receptor antagonists superfused (for 20 min) prior to and during (90 s) the superfusion of ATP (EC_{70} value, 3 or $10 \mu\text{M}$ for $rP2Y_4$ and $rP2Y_2$, respectively) at $rP2Y_4$ receptors (a) and $rP2Y_2$ receptors (b) expressed in *Xenopus* oocytes. Data are expressed as mean \pm s.e.m. ($n = 3-4$). IC_{50} values and, where possible, Hill coefficients (n_H) are given in Table 1. (c, d) Concentration/responses (C/R) curves for ATP activation of $rP2Y_4$ receptors (c) and $rP2Y_2$ receptors (d) in the presence of either Reactive blue 2 (RB-2, in c) or suramin (in d) at the given concentrations. In the presence these antagonists, the C/R curves were shifted to the right, without reducing the maximum agonist response, indicating competitive antagonism. From these rightward shifts, pA_2 values (RB-2, 6.43; suramin, 5.40) were determined by Schild analysis (not shown).




Figure 4 Modulatory actions of extracellular pH. (a, b) Concentration/response (C/R) curves for ATP activation of $rP2Y_4$ receptors (a) and $rP2Y_2$ receptors (b) expressed in *Xenopus* oocytes and examined at the levels of extracellular pH indicated. Data are expressed as mean \pm s.e.m. ($n = 3-7$). The EC_{50} values and Hill coefficients (n_H) are given in Table 2. Further details on the forms of ATP-ion species activating these two P2Y receptors are given in the text and Table 3.

Table 2 H^+ modulation of agonist potency at recombinant P2Y receptors

	$rP2Y_4$		$rP2Y_2$	
	EC_{50} (μM)	n_H	EC_{50} (μM)	n_H
<i>ATP</i>				
pH 8.0	1.33 ± 0.47	1.2 ± 0.2	5.80 ± 0.63	1.2 ± 0.2
pH 7.5	1.46 ± 0.82	1.0 ± 0.2	2.51 ± 0.93	1.1 ± 0.3
pH 6.5	0.53 ± 0.09	1.0 ± 0.2	4.57 ± 0.60	1.0 ± 0.3
pH 5.5	0.15 ± 0.13	1.3 ± 0.3	5.96 ± 0.73	1.1 ± 0.3
<i>UTP</i>				
pH 7.5	1.79 ± 0.92	1.3 ± 0.3	3.63 ± 0.28	0.9 ± 0.3
pH 5.5	0.23 ± 0.08	0.9 ± 0.1	3.04 ± 0.49	1.1 ± 0.3

Potency indices (EC_{50}) and Hill coefficients (n_H) for ATP/UTP activation of $rP2Y_4$ receptors (left) and $rP2Y_2$ receptors (right) expressed in *Xenopus* oocytes and examined under different levels of extracellular pH (pH 8.0–5.5). Data are expressed as mean \pm s.e.m. ($n = 3-6$).

at pH 7.5), with similar changes in potency when using UTP (Table 2), and also for Ap_4A (data not shown). Use of the program “Bound and Determined” (v.4.35) (Brooks & Storey, 1992) showed that the proportional changes in agonist potency at $rP2Y_4$ were unrelated to the levels of free ATP (i.e. ATP^{4-})

Table 3 Analysis of amounts of ATP-ion species in EC₅₀ concentrations

	<i>rP2Y₄</i>				<i>RP2Y₂</i>			
	pH 8.0	pH 7.5	pH 6.5	pH 5.5	pH 8.0	pH 7.5	pH 6.5	pH 5.5
Mean EC ₅₀ (nM)	1332	1458	529	145	5801	2511	4566	5955
	<i>ATP species (nM)</i>				<i>ATP species (nM)</i>			
ATP ⁴⁻	106	115	38	6	460	197	329	230
HATP ³⁻	4	13	43	63	16	22	373	2594
H ₂ ATP ²⁻	0	0	0	3	0	0	2	130
NaATP ³⁻	182	198	66	10	794	340	568	395
KATP ³⁻	3	4	1	0	15	6	10	7
CaATP ²⁻	849	922	307	45	3698	1590	2648	1842
Ca ₂ ATP	187	203	68	10	817	352	585	407
CaHATP ⁻	1	2	6	9	2	3	50	351
<i>Total</i>	1332	1457	529	146	5802	2510	4565	5956

Computational determinations of the amounts (in nM) of each ATP-ion species present in the oocyte bathing solution (Ringer's solution; composition in Methods, temperature 18°C) for the mean concentration of ATP (in nM) evoking the 50% maximum response (EC₅₀) at rP2Y₄ receptors (left) and rP2Y₂ receptors (right) examined at four extracellular pH levels (pH 8.0–5.5). The amounts of each ATP-ion species were determined by the programme "Bound and Determined" (Brooks & Storey, 1992).

(Table 3). The calculated levels for ATP⁴⁻ ion species progressively decreased with acidification, although agonist potency had increased. Also, changes in the calculated levels of other major ATP-ion species did not match the proportional increase in EC₅₀ values upon changing to lower extracellular pH levels. These computational results suggested that the effect of pH was on the receptor and not on the ligand. Changing extracellular pH had no significant effect ($P > 0.1$) on the potency of either RB-2 or suramin at rP2Y₄ and P2Y₂ receptors.

Modulatory actions of divalent cations

Where extracellular pH has a strong modulatory effect, it is not uncommon for metal cations (especially Zn²⁺) to modulate the same receptor subtype – whether they are nonpurinergic G protein-coupled receptors (LGICs) and G protein-coupled receptors (GPCRs) (Smart *et al.*, 1994) or purinergic LGICs (Wildman *et al.*, 1998) and GPCRs (Hiley *et al.*, 1995; Mundell & Kelly, 1998). Here, a modulatory effect by extracellular Zn²⁺ ions was revealed at both P2Y subtypes (Figure 5a,b).

For rP2Y₄, Zn²⁺ ions (0.1–1000 μM) coapplied with the ATP inhibited agonist-evoked responses in a concentration-dependent manner (IC₅₀, 29.8 ± 3.1 μM; slope, -1.2 ± 0.1; $n = 4$) (Figure 5a). ATP responses were further inhibited by Zn²⁺ ions, if this cation was applied either for 15 min (IC₅₀, 4.0 ± 0.4 μM; slope, -1.0 ± 0.1; $n = 4$) or for 30 min (IC₅₀, 2.5 ± 0.6 μM; slope, -1.0 ± 0.1; $n = 4$) prior to addition of the agonist. The inhibitory effect of Zn²⁺ ions (10 μM) was abolished by the Zn²⁺ chelator, *N,N,N',N'*-tetrakis(2-pyridylmethyl)ethylenedi-amine (TPEN) (30 μM, 15 min preincubation), and restored upon washout of TPEN (data not shown). The modulatory effects of Zn²⁺ were reversed after washout.

For rP2Y₂, the modulatory effect of extracellular Zn²⁺ ions was much less pronounced (Figure 5b). Without preincubation, Zn²⁺ ions (1 mM) barely inhibited ATP responses, whereas a more potent inhibitory effect was seen following




Figure 5 Modulatory actions of Zn²⁺ ions. (a, b) Inhibition curves for Zn²⁺ ions (0.01–1000 μM) applied in the superfusate, either prior to (15, 30 min) or simultaneously (0 min), with ATP (EC₇₀ value, 3 or 10 μM for rP2Y₄ and rP2Y₂, respectively) at rP2Y₄ receptors (a) and rP2Y₂ receptors (b) expressed in *Xenopus* oocytes. Data are expressed as mean ± s.e.m. ($n = 4$). IC₅₀ values and further details are given in the text.

preincubation periods of either 15 min (IC₅₀, 186 ± 24 μM; slope, -1.2 ± 0.2; $n = 4$) or 30 min (IC₅₀, 198 ± 19 μM; slope, -1.3 ± 0.1; $n = 4$). This inhibitory effect was reversed after washout.

Discussion

The present investigations provided for the first time a direct comparison of two structurally distinct rat P2Y receptor subtypes that are known to be activated equally by ATP and UTP yet, at a superficial level, appear to share the same phenotype. In the past, some pharmacological procedures have been proposed to separate these two P2Y receptors (King *et al.*, 1998; also see a list of procedures in the Introduction), but few of these suggestions have been tested directly, or validated, until now.

The rat P2Y₄ receptor did not select for UTP, ATP, CTP, GTP or ITP when expressed in oocytes. All five of these nucleotides were equipotent at rP2Y₄ in oocytes, but not at rat P2Y₄ nor murine P2Y₄ expressed in 1321N1 cells, where only ATP and UTP are equipotent and CTP, GTP and ITP are significantly less potent (Kennedy *et al.*, 2000; Lazarowski *et al.*, 2001). In contrast, the human P2Y₄ receptor expressed in 1321N1 cells is only stimulated by three of these five nucleotides (UTP > ITP = GTP), while ATP is an antagonist (Kennedy *et al.*, 2000). Our EC₅₀ values for ATP and UTP at rP2Y₄ were approximately two-fold lower than equivalent data for other P2Y₄ isoforms expressed in 1321N1 cells, suggesting that we had not overexpressed rP2Y₄ and unduly altered the potency of ATP, UTP and other nucleotides by affecting receptor reserve (Kenakin, 2002). Others have shown that UTP potency can be higher than other nucleotides at rP2Y₄ receptors, depending on the type of G protein to which it is coupled (Filippov *et al.*, 2003). Thus, if the present findings are to be used as discriminatory tools of P2Y subtypes *in vivo*, it is important to apply our findings to P2Y receptors in rat tissues and coupling through the G_q/PLC β /IP₃/Ca²⁺ pathway.

In the present study, rat P2Y₂ was fully activated by the above five nucleotides, but only ATP and UTP were equipotent and the remainder were significantly less potent (i.e. ATP = UTP > CTP > GTP > ITP). UTP and ATP also are equipotent at mouse P2Y₂ (Lustig *et al.*, 1993) and human P2Y₂ (Parr *et al.*, 1994), although only CTP and GTP have been tested at murine P2Y₂ where they were found to be inactive (Erb *et al.*, 1993). The agonist activity of some or all of the above five nucleotides at species orthologues of P2Y₂ and P2Y₄ receptors suggests that the negatively charged triphosphate-ribose moiety common to each nucleotide is critically important for receptor activation, while the nature of the purine or pyrimidine moiety is much less important. In accordance with this suggestion, neutralization of positively charged amino-acid residues in TM6 and TM7 to limit triphosphate binding greatly reduced the potency of ATP and UTP at the mutated murine P2Y₂ receptor (Erb *et al.*, 1995).

In our experiments, we tried to match the levels of receptor expression for both P2Y subtypes by adjusting the amounts of injected cRNA so that the maximum ATP response by oocytes was of similar amplitude (about 1 μ A). While this is a relatively crude and imperfect procedure to control the P2Y receptor number, it helped us nonetheless to avoid the worst effects of differences in the receptor reserve on agonist potency (Kenakin, 2002) and allowed us to broadly compare the relative potencies of nucleotides at these two P2Y subtypes. Our findings indicate that rP2Y₄ was slightly more sensitive to ATP and UTP than at rP2Y₂ when receptor reserve appears to be similar, a conclusion which ran counter to earlier

suggestions that P2Y₂ is more sensitive. This earlier misconception probably resulted from one of us (King *et al.*, 1998) comparing potency data from different cell types expressing significantly different P2Y receptor numbers. Our findings also showed that the two P2Y receptor subtypes can be distinguished by differences in the relative potency of CTP (five-fold), GTP (seven-fold) and, notably, ITP (13-fold). In particular, the lower potency of ITP at rP2Y₂ is in agreement with earlier proposed procedures to separate these two P2Y receptor subtypes.

The pharmacological activity of BzATP was more clear-cut in our experiments: it activated rP2Y₂ and inhibited rP2Y₄. BzATP has been shown to activate murine P2Y₂ receptors (Erb *et al.*, 1993), but it has not been tested beforehand on other isoforms of P2Y₄ receptors. This synthetic compound also activates human P2Y₁₁ (Communi *et al.*, 1999) and inhibits rat and human P2Y₁ (Vigne *et al.*, 1999), so the power of BzATP to discriminate between P2Y₂ and P2Y₄ receptors in native tissues is not wholly reliable, although for that purpose BzATP could still be combined with other pharmacological tools. For example, human P2Y₁₁ is activated by α , β -meATP (van der Weyden *et al.*, 2000) and rat and human P2Y₁ receptors are fully activated by either 2-MeSADP or 2-MeSATP and blocked by PPADS. In the present study, α , β -meATP was inactive at both rP2Y₂ and rP2Y₄ and 2-MeSATP was a partial agonist, whereas neither receptor was potently inhibited by PPADS. We also found that ATP γ S was a full agonist at rP2Y₂ receptors and a partial agonist at rP2Y₄. The mouse P2Y₂ receptor is also fully activated by ATP γ S (Erb *et al.*, 1993). Taken together, ATP γ S may also help to distinguish P2Y₂ and P2Y₄ subtypes *in vivo*, but with the caveat that ATP γ S can also activate other P2Y (P2Y_{1,11}) and P2X (P2X_{1-3,5}) receptor subtypes. Thus, ATP γ S (like BzATP) could be used as a discriminatory tool for P2Y₂ and P2Y₄ receptors *in vivo*, but only in conjunction with other pharmacological agents to exclude the presence of other P2 receptor subtypes.

The observed actions of the adenine dinucleotides (Ap_nA family) revealed some similarities, and differences, between the two P2Y receptor subtypes. First, in the oocyte system, Ap₄A fully activated both P2Y receptor subtypes. Ap₄A also fully activated rat and human P2Y₄ receptors expressed in 1321N1 cells (Kennedy *et al.*, 2000). Ap₄A has never before been tested at rat and mouse P2Y₂ isoforms, but is known to be equipotent with ATP and UTP at human P2Y₂ (Hoyle *et al.*, 2001). In the present study, rat P2Y₂ was also activated by several other dinucleotides (Ap₃A, Ap₅A and Ap₆A). We have already shown in an earlier study that *Xenopus* oocytes do not rapidly break down Ap_nA molecules (Pintor *et al.*, 1996), and so the activity of many of the Ap_nA family at rat P2Y₂ cannot be explained by their breakdown to ATP. Therefore, the activity profile of the Ap_nA series might also be considered when trying to distinguish between P2Y₂ and P2Y₄ subtypes in rat tissues. Our data for the Ap_nA series mirrored the structure–activity relationship (SAR) for the P¹-P⁽ⁿ⁾-di(uridine-5')phosphate (Up_nU) series ($n = 2-6$) at the equivalent human P2Y receptors (Pendergast *et al.*, 2001). Thus human and rat P2Y₄ isoforms are only activated fully by the tetraphosphates of the Up_nU and Ap_nA series, respectively, and these tetraphosphates are as potent as either UTP or ATP. On the other hand, human and rat P2Y₂ isoforms are activated by the same range of Up_nU and Ap_nA compounds – with the

tetraphosphates most active and almost as potent as either UTP and ATP, other dinucleotides marginally less potent and the diphosphates being either weakly active or inactive.

Prior to this study, it had been shown that suramin shifted the *C/R* curve to the right for UTP acting on rat aortic strips but had no effect on the *C/R* for UTP acting on canine tracheal epithelium, indicating that there may be two subtypes of P2U receptors *in vivo* (Dainty *et al.*, 1994). Examples of P2U/P2Y₂-like receptors in other tissues have also been reported to show different sensitivities to suramin (Ralevic & Burnstock, 1998). Rat P2Y₂ was competitively antagonised by suramin (pA₂, 5.40) (this study) and also at human P2Y₂ (pA₂, 4.26) (Charlton *et al.*, 1996). Suramin has not yet been tested on canine P2Y₂ (Zambon *et al.*, 2000). In contrast, suramin was effective only at high concentrations at rat P2Y₄ receptors (mean IC₅₀, 1 mM). It is possible that blockade by high concentrations of suramin (100 μM and greater) was due to the inhibition of G-protein signalling rather than, or as well as, P2Y receptor blockade (Freissmuth *et al.*, 1999). The observed differences in suramin sensitivity at rP2Y₂ and rP2Y₄ might account for the possibility of two P2U receptors, *in vivo*.

Of the other antagonists tested, rat P2Y₄ was competitively antagonised by RB-2 (pA₂, 6.43), which contrasted with negative data for rP2Y₂ and provided another way of differentiating between these two P2Y subtypes. The P2X receptor antagonist TNP-ATP also was inactive at both rP2Y₂ and rP2Y₄ receptors – raising the possibility that TNP-ATP might be one of the few P2 antagonists selective only for ATP-gated ion channels. We found that rat P2Y₄ was incompletely blocked by PPADS (by 47% at 10 mM), as also seen with PPADS at human P2Y₄ receptors expressed in 1321N1 cells (30% at 100 μM) (Charlton *et al.*, 1996). In contrast, it has been reported that PPADS blocked both the rat P2Y₄ (mean IC₅₀, 25 M) and mouse P2Y₄ receptors (mean IC₅₀, 45 μM) expressed in 1321N1 cells (Suarez-Heurta *et al.*, 2001). We did protect PPADS for white light, which promotes the breakdown of the azo-bridge in PPADS, and its limited activity in our hands cannot be due to degradation. Also, differences in PPADS activity at rP2Y₄ cannot be due to the oocyte expression system since the antagonist is not active at hP2Y₄ in 1321N1 cells. Also, we did not find any significant differences in antagonist activity when the extracellular pH was changed. Therefore, at this time, we cannot explain the differences in the activity of PPADS at rP2Y₄ seen in separate studies and, therefore, caution against the use of PPADS to identify the P2Y₄ subtype.

Another new aspect of the present study involved the modulation of agonist activity at P2Y receptors. This is the first time that extracellular pH has been shown to affect recombinant P2Y receptors, although H⁺ ions are known to enhance agonist potency at native P1(A_{2A}) receptors (Hiley *et al.*, 1995) and recombinant P2X subtypes – especially rat P2X₂ receptors (King *et al.*, 1996b). This potentiating effect was peculiar to the rP2Y₄ subtype, whereas agonist potency at the rP2Y₂ subtype was unaffected. This latter negative finding agreed with an earlier study of native P2U receptors in adenosine-5'-triphosphate (BPAE) cells, which were believed to be activated by free ATP (ATP⁴⁻) and unaffected by changing pH (Lustig *et al.*, 1992).

We carried out a computational analysis of the available ATP-ion species, using “*Bound and Determined*” (Brooks &

Storey, 1992), and, at the four pH levels tested, the amounts of ATP⁴⁻ present (197–460 nM) were proportionally similar to the EC₅₀ ratios determined for rP2Y₂ receptors. However, in our experiments with rP2Y₄, the available ATP⁴⁻ levels progressively decreased (106–6 nM) with extracellular acidification – even though agonist potency was progressively enhanced. Thus, free ATP (ATP⁴⁻) may be able to activate rP2Y₂ receptors, as suggested for P2U receptors in BPAE cells (Lustig *et al.*, 1992), but this did not seem to be the case for rP2Y₄ receptors since our EC₅₀ values were not in proportion with the available amounts of free ATP.

It was not possible to identify the ATP-ion species that activated rP2Y₄ receptors and, instead, the observed pH-induced changes in agonist potency may involve an action on the receptor itself. The pH modulation of agonist potency at the P2X₂ receptor is thought to be due to the acidification of histidine residue(s) close to the ATP-binding site (Clyne *et al.*, 2002a). However, the amino-acid sequences of rP2Y₄ and rP2Y₂ show eight conserved histidine residues and only 1 unique histidine in the intracellular C-terminus of rP2Y₄ – a site unlikely to be instantly accessible to extracellular pH. The substitution of cysteine with alanine residues can also blunt the pH modulation of agonist potency at P2X₂ receptors (Clyne *et al.*, 2002b). Of the 13 cysteine residues found in rP2Y₄, 10 are shared with rP2Y₂ receptors. The three unique cysteine residues are located on IL2, TM4 and C-terminus of rP2Y₄. The precise contribution of these cysteine residues – particularly in TM4 – awaits mutational analysis of the P2Y₄ receptor.

The inhibitory action of Zn²⁺ ions on agonist activity represented another novel finding for P2Y receptors. This divalent cation caused an inhibition of rP2Y₄ receptors when coapplied with ATP, and the immediacy of its effect suggested an extracellular site-of-action – perhaps one of the histidine and/or cysteine residues on rP2Y₄, since these residues have also been causally linked with the modulatory actions of Zn²⁺ ions at P2X₂ receptors (Clyne *et al.*, 2002a, b). However, the actions of Zn²⁺ ions were not duplicated by H⁺ ions at rP2Y₄ receptors and it seems unlikely that the same histidine and cysteine residues can be involved in the modulatory effects of both ion species yet still have divergent effects. Zn²⁺ effects were time dependent and enhanced by preincubation, which might indicate additional sites-of-action – either deeper in the agonist-binding pocket or at an intracellular site. Intracellular Zn²⁺ ions can potentiate agonist responses at A_{2A} and A_{2B} receptors in NG108-15 cells, by slowing down the rate of GRK2 kinase-mediated receptor desensitisation, and can also affect the rate of desensitisation at β₂-adrenoceptors and 5-HT₄ receptors by a similar mechanism (Mundell & Kelly, 1998, and references therein). However, we observed an inhibitory effect – not a potentiation – with Zn²⁺ ions at P2Y receptors, suggesting that these cations might not easily gain access to the inside of oocytes.

In summary, the pharmacological profiles of rat P2Y₂ and rat P2Y₄ were more divergent than previously supposed. There were differences in agonist potency for naturally occurring nucleotides, greater differences in the selectivity of dinucleotides and significant differences in the pharmacological actions of some synthetic nucleotides. The actions of extracellular pH on ATP/UTP activity were significantly different at these two P2Y receptors, as was the blocking activity of a range of P2 receptor antagonists on ATP/UTP

responses. Finally, agonist activity was modulated by Zn²⁺ ions at the rP2Y₄ receptor, which was much more sensitive than rP2Y₂. Collectively, these pharmacological differences should help to determine the presence of either of the P2Y receptor subtype in rat cell lines and tissues.

References

- ABBRACCHIO, M.P., BOEYNAEMS, J.M., BARNARD, E.A., BOYER, J.L., KENNEDY, C., MIRAS-PORTUGAL, M.P., KING, B.F., GACHET, C., JACOBSON, K.A., WEISMAN, G.A. & BURNSTOCK, G. (2003). Characterization of the UDP-glucose receptor (renamed here the P2Y₁₄ receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol. Sci.*, **24**, 52–55.
- BARNARD, E.A., BURNSTOCK, G. & WEBB, T.E. (1994). G protein-coupled receptors for ATP and other nucleotides: a new receptor family. *Trends Pharmacol. Sci.*, **15**, 67–70.
- BOGDANOV, Y.D., WILDMAN, S.S., CLEMENTS, M.P., KING, B.F. & BURNSTOCK, G. (1998). Molecular cloning and characterization of rat P2Y₄ nucleotide receptor. *Br. J. Pharmacol.*, **124**, 428–430.
- BROOKS, S.P. & STOREY, K.B. (1992). Bound and determined: a computer program for making buffers of defined ion concentrations. *Anal. Biochem.*, **201**, 119–126.
- CHARLTON, S.J., BROWN, C.A., WEISMAN, G.A., TURNER, J.T., ERB, L. & BOARDER, M.R. (1996). Cloned and transfected P2Y₄ receptors: characterization of a suramin and PPADS-insensitive response to UTP. *Br. J. Pharmacol.*, **119**, 1301–1303.
- CLYNE, J.D., LAPOINTE, L.D. & HUME, R.I. (2002a). The role of histidine residues in modulation of the rat P2X₂ purinoceptor by zinc and pH. *J. Physiol. (Lond.)*, **539**, 347–359.
- CLYNE, J.D., WANG, L.F. & HUME, R.I. (2002b). Mutational analysis of the conserved cysteines of the rat P2X₂ purinoceptor. *J. Neurosci.*, **22**, 3873–3880.
- COMMUNI, D., PIROTON, S., PARMENTIER, M. & BOEYNAEMS, J.M. (1995). Cloning and functional expression of a human uridine nucleotide receptor. *J. Biol. Chem.*, **270**, 30849–30852.
- COMMUNI, D., ROBAYE, B. & BOEYNAEMS, J.M. (1999). Pharmacological characterization of the human P2Y₁₁ receptor. *Br. J. Pharmacol.*, **128**, 1199–1206.
- DAINTY, I.A., POLLARD, C.E., ROBERTS, S.M., FRANKLIN, M., MCKECHNIE, K.C.W. & LEFF, P. (1994). Evidence for subdivision of P2U-purinoceptors based on suramin sensitivity. *Br. J. Pharmacol.*, **112**, 578P.
- DUBYAK, G.R. (1991). Signal transduction by P2-purineric receptors for extracellular ATP. *Am. J. Respir. Cell. Mol. Biol.*, **4**, 295–300.
- DUBYAK, G.R. & EI-MOATASSIM, C. (1993). Signal transduction via P2-purineric receptors for extracellular ATP and other nucleotides. *Am. J. Physiol.*, **265**, C577–606.
- ERB, L., LUSTIG, K.D., SULLIVAN, D.M., TURNER, J.T. & WEISMAN, G.A. (1993). Functional expression and photoaffinity labeling of a cloned P2U purineric receptor. *Proc. Nat. Acad. Sci. U.S.A.*, **90**, 10449–10453.
- ERB, L., GARRAD, R., WANG, Y., QUINN, T., TURNER, J.T. & WEISMAN, G.A. (1995). Sited-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. *J. Biol. Chem.*, **270**, 4185–4188.
- FILIPPOV, A.K., SIMON, J., BARNARD, E.A. & BROWN, D.A. (2003). Coupling of the nucleotide P2Y₄ receptor to neuronal ion channels. *Br. J. Pharmacol.*, **138**, 400–406.
- FREISSMUTH, M., WALDHOER, M., BOFILL-CARDONA, E. & NANOFF, C. (1999). G protein antagonists. *Trends Pharmacol. Sci.*, **20**, 237–245.
- HILEY, C.R., BOTTRILL, F.E., WARNOCK, J. & RICHARDSON, P.J. (1995). Effects of pH on responses to adenosine, CGS 21680, carbachol and nitroprusside in the isolated perfused superior mesenteric arterial bed of the rat. *Br. J. Pharmacol.*, **116**, 2641–2646.
- HOYLE, C.H.V., HILDERMAN, R.H., PINTOR, J.J., SCHLUTER, H. & KING, B.F. (2001). Diadenosine polyphosphates as extracellular signal molecules. *Drug Devel. Res.*, **52**, 260–273.
- KENAKIN, T. (2002). Drug efficacy at G protein-coupled receptors. *Ann. Rev. Pharmacol. Toxicol.*, **42**, 349–379.
- KENNEDY, C., QI, A.D., HEROLD, C.L., HARDEN, T.K. & NICHOLAS, R.A. (2000). ATP, an agonist at the rat P2Y₄ receptor, is an antagonist at the human P2Y₄ receptor. *Mol. Pharmacol.*, **57**, 926–931.
- KING, B.F., TOWNSEND-NICHOLSON, A. & BURNSTOCK, G. (1998). Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. *Trends Pharmacol. Sci.*, **19**, 506–514.
- KING, B.F., WANG, S. & BURNSTOCK, G. (1996a). P2 purinoceptor-activated inward currents in follicular oocytes of *Xenopus laevis*. *J. Physiol. (Lond.)*, **494**, 17–28.
- KING, B.F., ZIGANSHINA, L.E., PINTOR, J. & BURNSTOCK, G. (1996b). Full sensitivity of P2X₂ purinoceptor to ATP revealed by changing extracellular pH. *Br. J. Pharmacol.*, **117**, 1371–1373.
- LAZAROWSKI, E.R., ROCHELLE, L.G., O'NEAL, W.K., RIBEIRO, C.M., GRUBB, B.R., ZHANG, V., HARDEN, T.K. & BOUCHER, R.C. (2001). Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. *J. Pharmacol. Exp. Ther.*, **297**, 43–49.
- LUSTIG, K.D., SHIAU, A.K., BRAKE, A. & JULIUS, D. (1993). Expression cloning of an ATP receptor from mouse neuroblastoma cells. *Proc. Nat. Acad. Sci. U.S.A.*, **90**, 5113–5117.
- LUSTIG, K.D., SPORTIELLO, M.G., ERB, L. & WEISMAN, G.A. (1992). A nucleotide receptor in vascular endothelial cells is specifically activated by the fully ionized forms of ATP and UTP. *Biochem. J.*, **284**, 733–739.
- MUNDELL, S.J. & KELLY, E. (1998). Evidence for co-expression and desensitization of A_{2A} and A_{2B} adenosine receptors in NG108-15 cells. *Biochem. Pharmacol.*, **55**, 595–603.
- NGUYEN, T., ERB, L., WEISMAN, G.A., MARCHESE, A., HENG, H.H., GARRAD, R.C., GEORGE, S.R., TURNER, J.T. & O'DOWD, B.F. (1995). Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. *J. Biol. Chem.*, **270**, 30845–30848.
- O'CONNOR, S.E., DAINTY, I.A. & LEFF, P. (1991). Further subclassification of ATP receptors based on agonist studies. *Trends Pharmacol. Sci.*, **12**, 137–141.
- PARR, C.E., SULLIVAN, D.M., PARADISO, A.M., LAZAROWSKI, E.R., BURCH, L.H., OLSEN, J.C., ERB, L., WEISMAN, G.A., BOUCHER, R.C. & TURNER, J.T. (1994). Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. *Proc. Nat. Acad. Sci. U.S.A.*, **91**, 3275–3279.
- PENDERGAST, W., YERXA, B.R., DOUGLASS-III, J.G., SHAVER, S.R., Dougherty, R.W., REDICK, C.C., SIMS, I.F. & RIDEOUT, J.L. (2001). Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. *Bioorg. Med. Chem. Lett.*, **11**, 157–160.
- PINTOR, J., KING, B.F., ZIGANSHIN, A.U., MIRAS-PORTUGAL, M.T. & BURNSTOCK, G. (1996). Diadenosine polyphosphate-activated inward and outward currents in follicular oocytes of *Xenopus laevis*. *Life Sci.*, **59**, 179–184.
- RALEVIC, V. & BURNSTOCK, G. (1998). Receptors for purines and pyrimidines. *Pharmacol. Rev.*, **50**, 413–492.
- SEYE, C.I., GADEAU, A.P., DARET, D., DUPUCH, F., ALZIEU, P., CAPRON, L. & DESGRANGES, C. (1997). Overexpression of P2Y₂ purinoceptor in intimal lesions of the rat aorta. *Arterioscler. Thromb. Vasc. Biol.*, **17**, 3602–3610.
- SMART, T.G., XIE, X. & KRISHEK, B.J. (1994). Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. *Prog. Neurobiol.*, **42**, 393–441.
- SUAREZ-HUERTA, N., POUILLON, V., BOEYNAEMS, J.M. & ROBAYE, B. (2001). Molecular cloning and characterization of the mouse P2Y₄ nucleotide receptor. *Eur. J. Pharmacol.*, **416**, 197–202.

- VAN DER WEYDEN, L., ADAMS, D.J., LUTTRELL, B.M., CONIGRAVE, A.D. & MORRIS, M.B. (2000). Pharmacological characterisation of the P2Y₁₁ receptor in stably transfected haematological cell lines. *Mol. Cell. Biochem.*, **213**, 75–81.
- VIGNE, P., HECHLER, B., GACHET, C., BREITTMAYER, J.P. & FRELIN, C. (1999). Benzoyl ATP is an antagonist of rat and human P2Y₁ receptors and of platelet aggregation. *Biochem. Biophys. Res. Commun.*, **256**, 94–97.
- VON KÜGELGEN, I., HAUSSINGER, D. & STARKE, K. (1987). Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **336**, 556–560.
- WEBB, T.E., HENDERSON, D.J., ROBERTS, J.A. & BARNARD, E.A. (1998). Molecular cloning and characterization of the rat P2Y₄ receptor. *J. Neurochem.*, **71**, 1348–1357.
- WILDMAN, S.S., KING, B.F. & BURNSTOCK, G. (1998). Zn²⁺ modulation of ATP-responses at recombinant P2X₂ receptors and its dependence on extracellular pH. *Br. J. Pharmacol.*, **123**, 1214–1220.
- WILDMAN, S.S., TURNER, C., BURNSTOCK, G., UNWIN, R.J. & KING, B.F. (2002). P2Y₄ abundance in rat kidney epithelial cysts and its properties *in vitro*. *J. Am. Soc. Nephrol.*, **13**, F-P0272 (abstract).
- ZAMBON, A.C., HUGHES, R.J., MESZAROS, J.G., WU, J.J., TORRES, B., BRUNTON, L.L. & INSEL, P.A. (2000). P2Y₂ receptor of MDCK cells: cloning, expression, and cell-specific signalling. *Am. J. Physiol.*, **279**, 1049–1052.

(Received August 8, 2003

Revised September 4, 2003

Accepted September 16, 2003)